Plain-English translation of NCT06319872 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers want to know if disulfiram (Antabuse®)—a medication already used to help people stop drinking—might also improve vision in patients with retinal degeneration, a group of eye diseases that cause progressive vision loss. In animal studies, this medication appeared to help preserve sight by changing how the eye processes certain chemicals. This trial will test whether the same benefit happens in people.
Currently, there are few treatment options for inherited retinal diseases and some forms of age-related vision loss. If this medication can help preserve or improve vision in people living with these conditions, it could offer a new hope for patients who have limited choices.
You likely qualify if…
You likely don't qualify if…
You will take either the study medication or a placebo (inactive pill) by mouth every day for 180 days (about 6 months). During this time, you'll have regular eye exams to measure your vision and check for any changes or side effects. You'll also need to commit to staying completely alcohol-free throughout the study period. The research team will monitor your eye health closely using specialized imaging and vision tests.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
University of Rochester
Enrollment target
~15 participants
Started
May 2025
Primary completion
May 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Evan Burr
University of Rochester
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.